Citation

Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong ICK, Zuddas A, Steinhausen HC, Taylor E, European Guidelines Group. Eur. Child Adolesc. Psychiatry 2011; 20(1): 17-37.

Copyright

(Copyright © 2011, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s00787-010-0140-6

PMID

21042924

PMCID

PMC3012210

Abstract

The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

Language: en

Keywords

Humans; Child; Risk Assessment; Cardiovascular Diseases; Substance-Related Disorders; Europe; Suicide, Attempted; Drug Administration Schedule; Clinical Trials as Topic; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Propylamines; Monitoring, Physiologic; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Drug Tolerance; Drug Utilization Review; Drug Dosage Calculations